Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

 

Gastric & Breast Cancer
DOI: 10.2122/gbc.2005.0040

VIEWPOINT

The complexity in deciding for BRCA genetic testing insurance coverage and risks of missing young carriers by strict criteria

Ioannis Georgiou, PhD, Michael Fatouros, MD, Ioannis Arampatzis, MD, Demosthenis Ziogas, MD, Evangelos Paraskevaidis, MD, Angelos M Kappas, MD, Dimitrios H Roukos, MD.
Abstract

Criteria suggestive of hereditary breast ovarian cancer (HBOC) syndrome that warrant genetic testing are not consistent. The body of literature data is limited and evidence about cost-effectiveness of genetic testing is lacking. Insurance coverage of genetic testing among various countries is not clear and the thresholds (10 to 20%) of the probability for positive genetic testing considerably vary in the national recommendations from UK , US, Germany and Sweden .

Should more or less strict clinical criteria used for decisions about genetic testing? Considering the risk of missing a young BRCA carrier and the associated high risk of death for this woman on one hand and the high costs and insurance coverage of the other, we attempt to approach this key question.

Find Delta Dental, MetLife Dental, Aetna Dentist, New York Dentist, San Francisco Dentist, Boston Dentist, Chicago Dentist, Los Angeles Dentist & San Diego Dentist at DoctorsImprovingHealthcare.org.

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 3 February 2004